HBIO vs DBVT vs ALKS vs ITRN vs PRGO

For growth investors, Ituran Location and Control Ltd.

(ITRN) is the stronger pick with 6. 8% revenue growth year-over-year, versus -8. 1% for Harvard Bioscience, Inc. (HBIO). Ituran Location and Control Ltd. (ITRN) offers the better valuation at 20. 2x trailing P/E (18. 4x forward), making it the more compelling value choice. Analysts rate Harvard Bioscience, Inc. (HBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Ituran Location and Control Ltd.

(ITRN) is the cheapest at 20. 2x versus Alkermes plc at 24. 8x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Ituran Location and Control Ltd.

(ITRN) delivered a total return of +180. 2%, compared to -90. 7% for Harvard Bioscience, Inc. (HBIO). Over 10 years, the gap is even starker: ITRN returned +243. 1% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Harvard Bioscience, Inc. 's 2. 05β — meaning HBIO is approximately 106% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Ituran Location and Control Ltd. (ITRN) carries a lower debt/equity ratio of 2% versus 3% for Harvard Bioscience, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ituran Location and Control Ltd.

(ITRN) is pulling ahead at 6. 8% versus -8. 1% for Harvard Bioscience, Inc. (HBIO). On earnings-per-share growth, the picture is similar: Ituran Location and Control Ltd. grew EPS 8. 1% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -65. 5% for Harvard Bioscience, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ITRN leads at 21. 4% versus -0. 7% for HBIO. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 18. 4x for Ituran Location and Control Ltd. — 12. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.

In this comparison, PRGO (9.

8% yield), ITRN (3. 2% yield) pay a dividend. HBIO, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ituran Location and Control Ltd.

(ITRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16), 3. 2% yield, +243. 1% 10Y return). Harvard Bioscience, Inc. (HBIO) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ITRN: +243. 1%, HBIO: -75. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HBIO (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and ITRN (Technology) and PRGO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HBIO is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; ITRN is a small-cap income-oriented stock; PRGO is a small-cap income-oriented stock. ITRN, PRGO pay a dividend while HBIO, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.